10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial health with a $482 million cash reserve and a focus on product innovation and market expansion. The Q&A reveals confidence in spatial consumables and biopharma revenue growth, despite CapEx headwinds. The strategic focus on AI and translational research, along with a strong balance sheet, supports positive sentiment. The market cap suggests moderate stock volatility, leading to a predicted positive stock price movement of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue for Q4 2025 $166 million, representing 1% growth year-over-year. The growth was attributed to a challenging operating environment balanced by continued momentum in the business and an unanticipated budget flush late in the quarter.
Full Year 2025 Revenue $599 million, excluding $44 million of upfront revenue related to patent litigation settlements. This reflects steady progress across the business despite a challenging and unpredictable year.
Single-cell consumables revenue for Q4 2025 Up 3% year-over-year, supported by double-digit growth in reaction volumes, driven in part by the lower-priced Flex assay.
Spatial consumables revenue for Q4 2025 Up 14% year-over-year, driven by Xenium consumables.
Total instrument revenue for Q4 2025 Declined 36% year-over-year, with Chromium instrument revenue down 44% and spatial instrument revenue down 30%. The decline was due to ongoing funding challenges for capital equipment, though there was a sequential uptick due to year-end capital spending.
Geographical Revenue for Q4 2025 Americas revenue declined 6%, while EMEA and APAC grew 7% and 9%, respectively. The decline in the Americas was due to continued softness in the U.S. academic and government funding environment, while EMEA and APAC benefited from late-quarter orders and solid performance, respectively.
Gross Margin for Q4 2025 68%, up from 67% in the prior-year period. The increase was driven by lower inventory write-downs, lower royalty and warranty costs, partially offset by higher manufacturing costs.
Operating Expenses for Q4 2025 Decreased 18% year-over-year, primarily driven by lower outside legal expenses and lower personnel costs.
Cash Balance at the end of 2025 $523 million, up $130 million from the end of 2024. The increase reflects disciplined cost management and focused execution across the business.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Flex Apex Assay: Launched in 2025, it represents a significant advancement in the Chromium platform, offering high performance, flexible inputs, and lower costs. It has become the most popular single-cell assay by volume in Q4 2025.
Visium HD 3 Prime and HD Cell Segmentation: Launched to enable broader transcriptome analysis and precise tissue structure visualization in spatial analysis.
Xenium RNA and Protein: Introduced multimodal analysis in a single workflow, expanding spatial portfolio capabilities.
Geographic Revenue Performance: Americas revenue declined 6%, while EMEA and APAC grew by 7% and 9%, respectively. EMEA growth was driven by late-quarter orders, and APAC performed as expected.
Adoption in Translational Research: Increased adoption in translational research, particularly in oncology and autoimmunity, driven by advances in scale, cost, and compatibility with clinical samples.
Revenue Growth: Achieved $166 million in Q4 revenue, exceeding guidance, and $599 million for the year, excluding $44 million from patent litigation settlements.
Cost Management: Reduced operating expenses by 18% in Q4, driven by lower legal and personnel costs, and increased cash balance by $130 million year-over-year.
AI and Biological Data Integration: Collaborations with Chan Zuckerberg Initiative, Arc Institute, and Cancer Research Institute to generate large-scale biological data for AI-driven discovery.
Clinical Applications: Collaborations with Dana-Farber Cancer Institute and Brigham and Women's Hospital to support clinical evidence generation and diagnostics development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Customer Spending and Capital Equipment Purchases: Customer spending remains subdued, and capital equipment purchases are particularly constrained, impacting revenue and growth opportunities.
Research Funding Dynamics: Uncertainty in research funding dynamics continues to impact customer sentiment and timing of purchasing decisions, creating challenges for revenue predictability.
Instrument Revenue Decline: Total instrument revenue declined 36%, with Chromium instrument revenue down 44% and spatial instrument revenue down 30%, reflecting ongoing funding challenges for capital equipment.
Geographic Revenue Variability: Revenue in the Americas declined 6%, driven by softness in the U.S. academic and government funding environment, while other regions showed modest growth.
Macroeconomic Environment: The broader macroeconomic environment remains challenging, with systemic turbulence in research funding dynamics affecting customer sentiment and purchasing decisions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company expects 2026 revenue to be in the range of $600 million to $625 million, representing 0% to 4% growth over 2025 (excluding upfront revenue related to patent litigation settlements).
Growth Expectations: Double-digit growth is anticipated for both single-cell consumables reactions and spatial consumables revenue in 2026.
Instrument Revenue Outlook: Capital expenditure funding is expected to remain constrained, continuing to put downward pressure on instrument revenue.
Market Conditions: The funding environment is expected to remain muted but stable, with systemic turbulence in research funding dynamics impacting customer sentiment and purchasing decisions.
Revenue Cadence for 2026: First quarter revenue is expected to be a larger percentage of full-year revenue compared to prior years, driven by late Q4 orders shipped in January.
Financial Profile: The company expects to sustain cost discipline and operating efficiencies achieved in 2025, driving further improvement in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you comment on ordering patterns and expectations for academic and pharma sectors, particularly around larger Perturb-seq studies and clinical applications?
A:The environment is similar to the past couple of quarters, with gradual improvement compared to the first half of '25. However, uncertainty remains in academic funding, staffing, and grant criteria. There is excitement around AI-driven projects for Perturb-seq applications, with products like Flex well-suited for these purposes. The potential for data generation for AI models is enormous.
Q:How should we think about volume and price trends for single-cell consumables into year-end and guidance for 2026?
A:In Q4 2025, reaction growth was over 30%, driven by the launch of Flex Apex. For 2026, Chromium consumables are expected to be flat at the midpoint of guidance, with various combinations of product mix and volumes contributing to this outcome. Continued pressure on CapEx and double-digit growth in spatial consumables are anticipated.
Q:What is the mix of Flex V1 versus V2 in Q4, and how will Flex Apex adoption impact pricing and growth in 2026?
A:Flex Apex launched in Q4 with strong initial adoption and positive customer feedback. It is too early to provide a breakdown of Flex versions or adoption cadence. Flex Apex is opening new use cases and experiments, with some customers switching from earlier versions or other products. Pricing dynamics vary, with some customers running more samples or paying less per sample. The focus is on driving additional volume.
Q:What are the expectations for the push into the clinical translational space and its impact on single-cell and spatial products?
A:There are two efforts: future clinical applications for diagnostics using single-cell and spatial technologies, and near-term translational research. The goal is to enable customers to develop clinical evidence and deploy technologies in clinical settings while building internal clinical evidence and a CLIA lab. Translational research offers significant opportunities, potentially as large as basic science, with products now supporting these applications.
Q:Which franchise will experience the largest impact from CapEx headwinds in 2026, and what is the outlook for biopharma revenue?
A:CapEx headwinds are expected to impact higher-end instruments more. Chromium instruments grew on a unit basis in 2025, and efforts will continue to address capital barriers. Biopharma revenue is expected to grow, with translational research and biomarker programs expanding downstream into drug development. The goal is for biopharma to eventually drive half of revenue.
Q:How are you thinking about the pricing and volume dynamics for Chromium consumables and the outlook for academic customer groups in different regions?
A:Chromium consumables are expected to be flat at the midpoint of guidance, with various combinations of price and volume contributing. Q4 2025 saw 30% reaction growth. While NIH funding remains under pressure, growth in China and EMEA is expected to offset U.S. weakness. The balance sheet is strong, providing flexibility for strategic investments.
Q:What is the confidence level in spatial consumables growth, and what is the cost profile outlook for 2026?
A:Spatial consumables growth in 2025 was driven entirely by Xenium, with double-digit growth expected in 2026. Customer sentiment and utilization rates are strong. Cost discipline will continue, with a focus on deploying resources wisely and maintaining a strong balance sheet.
Q:What are the Xenium reaction growth trends and the adoption cadence for Flex Apex?
A:Xenium reactions grew 34% in 2025, reaching 14,500. Flex Apex adoption is still early, with strong initial demand and positive feedback. The adoption cadence is uncertain, but early signs are encouraging.
Q:How are you addressing competitive dynamics in spatial and single-cell markets, and are there competitive pressures in guidance?
A:The company feels confident in its competitive position, with continuous innovation extending the gap with competitors. Xenium is growing faster than other offerings, and the company monitors the competitive landscape closely. Competitive pressures are not expected to materially impact guidance.
Q:What is the strategy for Visium, given its lack of growth in 2025?
A:Visium will continue to support specific customer use cases, but Xenium is seen as the best choice for most spatial analysis applications. Investments will focus on the Xenium platform, which is expected to drive future growth.
Q:What caused the timing shift in Q1 2026, and how does it impact guidance?
A:Unanticipated budget flush in late December 2025 led to some orders being fulfilled in January 2026, contributing a few million dollars to Q1. Q1 is expected to be about 24% of the full-year guidance midpoint.
Q:What is the timing and impact of scale technology integration, and how does it relate to AI customers?
A:Flex Apex is the primary solution for AI-driven projects, offering scalability, sensitivity, and robustness. Scale technology is not yet material to revenue but has potential for future products. The company is evaluating opportunities to integrate scale technology into its offerings.
Q:What are the plans for the CLIA lab, and how will it impact diagnostics customers and CapEx?
A:The CLIA lab is targeted for early 2027, focusing on tissue-based tumor profiling and blood-based autoimmune disease monitoring. Investments will be efficient, leveraging existing assets, with minimal P&L impact. The hybrid strategy aims to enable customer-developed clinical tests while accelerating internal efforts.
Q:What is the revenue opportunity from AI-driven projects, and how will the market evolve?
A:AI-driven projects are meaningful but still a small percentage of revenue. Flex Apex is well-suited for these applications. The demand for biological data generation is expected to grow continuously, with no cap on the upside. In silico experiments are not expected to replace biological data generation due to the complexity of biology.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the breakdown of Flex V1 versus V2 adoption, the adoption cadence for Flex Apex, and the exact pricing dynamics for Chromium consumables. They also did not provide clear guidance on the competitive pressures baked into the 2026 outlook or the specific timing and throughput expectations for scale technology integration.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Apex
Cancer
Chromium
FFPE blood
Institute
Principal
Visium
advance
approach
capital equipment
cash balance
cell consumables
cell technology
center
cohort study
collaboration
compatibility
cost discipline
customer sentiment
digit
driver
dynamic customer
evidence deployment
experiment
funding dynamic
generation
industry
literature
litigation settlement
momentum
oncology
purchasing decision
quality set
research funding
response
sentiment timing
therapy
timing purchasing
understanding
TXG Transcript
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
Positive2-14
The earnings call indicates strong financial health with a $482 million cash reserve and a focus on product innovation and market expansion. The Q&A reveals confidence in spatial consumables and biopharma revenue growth, despite CapEx headwinds. The strategic focus on AI and translational research, along with a strong balance sheet, supports positive sentiment. The market cap suggests moderate stock volatility, leading to a predicted positive stock price movement of 2% to 8% over the next two weeks.
10x Genomics, Inc. (TXG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript
Positive11-6
The company shows strong product development with new launches and acquisitions, optimistic guidance in spatial biology, and positive market trends. Despite cautious spending and macroeconomic uncertainties, management is confident in their leadership and growth potential, especially in China and Europe. The Q&A session highlighted enthusiasm for new products and strategic positioning against competitors. The market cap suggests moderate sensitivity, leading to a positive stock price prediction.
10x Genomics, Inc. (TXG) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-10
TXG Slides
TXG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
